Co-Authors
This is a "connection" page, showing publications co-authored by DAVID LONARD and JIN WANG.
Connection Strength
0.614
-
SRC-3 inhibition blocks tumor growth of pancreatic ductal adenocarcinoma. Cancer Lett. 2019 02 01; 442:310-319.
Score: 0.171
-
Development of potent small-molecule inhibitors to drug the undruggable steroid receptor coactivator-3. Proc Natl Acad Sci U S A. 2016 May 03; 113(18):4970-5.
Score: 0.143
-
Steroid Receptor Coactivator-3 (SRC-3/AIB1) as a Novel Therapeutic Target in Triple Negative Breast Cancer and Its Inhibition with a Phospho-Bufalin Prodrug. PLoS One. 2015; 10(10):e0140011.
Score: 0.138
-
Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma. Nat Commun. 2021 02 15; 12(1):1022.
Score: 0.050
-
Proteomic profiling identifies key coactivators utilized by mutant ERa proteins as potential new therapeutic targets. Oncogene. 2018 08; 37(33):4581-4598.
Score: 0.041
-
Targeting SRC Coactivators Blocks the Tumor-Initiating Capacity of Cancer Stem-like Cells. Cancer Res. 2017 08 15; 77(16):4293-4304.
Score: 0.039
-
Bufalin is a potent small-molecule inhibitor of the steroid receptor coactivators SRC-3 and SRC-1. Cancer Res. 2014 Mar 01; 74(5):1506-1517.
Score: 0.031